Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Unicycive Therapeutics (UNCY – Research Report). The associated price target remains the same with $7.50.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Ed Arce has given his Buy rating due to a combination of factors that highlight the competitive advantages of Unicycive Therapeutics’ oxylanthanum carbonate (OLC) in treating hyperphosphatemia in patients with chronic kidney disease. The pivotal study presented at the National Kidney Foundation Spring Clinical Meetings demonstrated that OLC significantly reduces pill burden, which is a major challenge for patient adherence to treatment. The study showed that patients taking OLC had their pill burden reduced by 50%, with a median of three tablets per day compared to six with previous treatments.
Furthermore, the study revealed that 70% of patients consistently adhered to OLC, compared to 58% with their prior phosphate binders. Additionally, a large majority of patients expressed a preference for OLC, with 79% favoring it over their previous treatments, and 98% found it easy to take. These results, combined with the expectation of FDA approval by the June 28, 2025 PDUFA date, underpin Arce’s confidence in the stock’s potential, leading to the Buy rating.
In another report released yesterday, Benchmark Co. also maintained a Buy rating on the stock with a $3.00 price target.